| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© Oxford University Press 2007.
NEWS |
Lapatinib Moves Forward in Inflammatory and Early HER2-Positive Breast Cancer Trials
| The first 150 words of the full text of this article appear below. |
Following on the heels of trastuzumab's success in HER2-positive breast cancer, lapatinib is moving rapidly through clinical development and already heading into trials in early breast cancer patients.
In its first major test, lapatinib, which also targets the HER2 receptor protein, improved disease-free survival in advanced breast cancer patients. More recent analyses show that the drug may have less cardiac toxic effects than trastuzumab and that it may work in disease settings where trastuzumab doesn't. The next big hurdle, however, will be whether lapatinib can improve clinical outcomes for patients with early-stage breast cancer.
"Lapatinib is certainly an active drug," said David Cameron, M.D., of the Western General Hospital in Edinburgh, Scotland, who has led some of the advanced breast cancer trials with lapatinib. "There are details that need working out about the drug, but basically we have proof of activity, hints that it may prevent [central nervous system]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Krol, R. E. Francis, A. Albergaria, A. Sunters, A. Polychronis, R. C. Coombes, and E. W.-F. Lam The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells Mol. Cancer Ther., December 1, 2007; 6(12): 3169 - 3179. [Abstract] [Full Text] [PDF]
|
|